The handling of biopharmaceuticals used in home-based therapy for cancer patients

• Published in: The International journal of pharmacy practice 2023-05, Vol.31 (3), p.298-304
• Main Authors: Hardebol, Lisa, Sikking, Charlotte, Florack, Marlou, Crul, Mirjam
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Biological Products - adverse effects; Europe; Humans; Neoplasms - drug therapy
• ISSN: 0961-7671; 2042-7174
• DOI: 10.1093/ijpp/riad008

Abstract Background Due to their low bioavailability, biopharmaceuticals are typically administered via injection or infusion in a hospital setting. Home-based therapy could be a valuable alternative for cancer patients. However, when exposed to stressors, such as high or low temperatures, particles can form in the biopharmaceutical solution, compromising the safety and efficacy of the biopharmaceutical. Aim This research investigated current practises with ready-to-administer biopharmaceuticals to determine if it is possible to offer cancer patients home-based therapy with monoclonal antibodies. Methods First, a questionnaire was conducted with the survey tool Survalyzer among Amsterdam UMC patients receiving immunoglobulins at home. Secondly, a web-based questionnaire (Survalyzer) was sent to pharmacists throughout Europe with a home-based therapy programme in place. Results The patient questionnaire (n = 52) showed that the biopharmaceutical is stored outside the recommended temperature range by 38% of the patients. Additionally, 17% of the patients do not recall getting any information on how to store their biopharmaceuticals, and 23% would like more information on the subject. Furthermore, the questionnaire amongst pharmacists (n = 21) showed that there is a lack of resources and logistical challenges when home-based therapy is applied to biopharmaceuticals used in cancer therapy. Conclusion Home-based therapy with monoclonal antibodies for cancer patients is challenging to implement.